Vanessa Research has been granted a positive orphan drug opinion by the European Medicines Agency for the drug Shylicine™ (patent pending).
The drug is used to treat microvillus inclusion disease, a rare pediatric disorder that causes chronic diarrhea.
Vanessa Research, a University of Connecticut Technology Incubation Program participant, has global offices in Hungary, Spain and Germany in addition to its Hamden, CT corporate campus.